Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01485744 · ClinicalTrials.gov registry record · Phase 1
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01485744: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01485744 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01485744, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
LDE225 is a new medicine that blocks the Hedgehog (Hh) pathway. The Hh pathway is a cascade of molecular events that control cell growth and have been linked with the development of many human cancers, including pancreatic cancer. Information from research studies suggests that LDE225 in combination with FOLFIRINOX may help to stop the growth of cancer cells. In this research study, the investigators are looking to determine the maximum dose of LDE225 in combination that can be given safely to patients with locally advanced or metastatic pancreatic cancer.
Interventions
- DRUG LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-12 |
| Est. Completion | 2019-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01485744
The ClinicalTrials.gov registry entry for NCT01485744 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan is the first listed.
NCT01485744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01485744 about?
NCT01485744 is a clinical study titled "LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer". LDE225 is a new medicine that blocks the Hedgehog (Hh) pathway. The Hh pathway is a cascade of molecular events that control cell growth and have been linked with the development of many human cancers, including pancreatic cancer. Information from research studies suggests that LDE225 in combination...
What is the current status of trial NCT01485744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2011-12. Estimated completion is 2019-11.
What interventions are being tested in trial NCT01485744?
The interventions under investigation include: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan (DRUG).
Who is sponsoring clinical trial NCT01485744?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.